Skip to main content
. Author manuscript; available in PMC: 2018 Dec 1.
Published in final edited form as: Crit Rev Oncol Hematol. 2017 Sep 8;120:217–226. doi: 10.1016/j.critrevonc.2017.09.003

Figure 3.

Figure 3

Recommended algorithm for managing bone health in women receiving aromatase inhibitor (AI) therapy for breast cancer. *If patients experience an annual decrease in bone mineral density (BMD) of ≥10% (using the same DXA absorptiometry machine), secondary causes of bone loss such as vitamin D deficiency should be evaluated and antiresorptive therapy initiated. Use lowest T-score from 3 sites.